Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

10359	Companies
215666	Keywords
145448	Articles
114230	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 03/24/2025 at 07:30, 1 year 1 month ago

Biophytis announces new non-clinical data further supporting its mission to pioneer the restoration of mobility in patients with obesity
Biophytis announces new preclinical study results showing combination of BIO101 and GLP-1 restores muscle strength and mobility in obesity patients. The company aims to pioneer mobility restoration in obese patients

Biophytis Preclinical Study BIO101 Obesity GLP-1
BRIEF

published on 03/17/2025 at 07:05, 1 year 1 month ago

Biophytis Publishes Promising Sarcopenia Trial Results

Biophytis Clinical Trial Sarcopenia BIO101 Phase 2 Results
REGULATED PRESS RELEASE

published on 03/17/2025 at 07:00, 1 year 1 month ago

Biophytis revolutionizes sarcopenia
Biophytis announces groundbreaking results from SARA-INT Phase II trial for BIO101 in sarcopenia, confirming Phase 3 readiness. Publication in JCSM highlights efficacy and safety

Biophytis Clinical Trial Sarcopenia Phase II SARA-INT
BRIEF

published on 03/06/2025 at 07:05, 1 year 2 months ago

Biophytis to Attend BIO-Europe Spring 2025 in Milan

Biophytis Biotechnology Drug Development BIO-Europe 2025 Aging Diseases
REGULATED PRESS RELEASE

published on 03/06/2025 at 07:00, 1 year 2 months ago

Biophytis announces its participation to the BIO-Europe Spring 2025 in Milan
Biophytis announces participation in BIO-Europe Spring 2025 in Milan. Chief Business Officer to attend meetings. Focus on lead drug candidate BIO101 in obesity and sarcopenia

Biophytis Sarcopenia BIO101 Obesity BIO-Europe Spring 2025
BRIEF

published on 02/25/2025 at 07:05, 1 year 2 months ago

Biophytis to Present at 15th International Conference on Frailty and Sarcopenia Research

Biophytis Sarcopenia BIO101 ICFSR 2025 Obesity Research
REGULATED PRESS RELEASE

published on 02/25/2025 at 07:00, 1 year 2 months ago

Biophytis announces its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)
Biophytis to participate in ICFSR 15th International Conference on Frailty and Sarcopenia Research, presenting data on BIO101 for obesity-associated sarcopenia. Event in Toulouse, March 12-14

Biophytis Sarcopenia ICFSR BIO101 Obesity
BRIEF

published on 02/11/2025 at 07:05, 1 year 2 months ago

Biophytis Outlines 2025 Strategic Plans

Strategic Partnerships Biophytis Clinical Development Obesity Treatment Sarcopenia
REGULATED PRESS RELEASE

published on 02/11/2025 at 07:00, 1 year 2 months ago

Biophytis unveils its outlook strategies for 2025
Biophytis unveils its strategic outlook for 2025, focusing on clinical development and commercialization plans for BIO101 (20-Hydroxyecdysone) in obesity and sarcopenia, with key partnerships and agreements

Biophytis Clinical Development BIO101 Obesity Strategic Outlook
BRIEF

published on 01/27/2025 at 07:05, 1 year 3 months ago

Biophytis to Participate in BIOMED FORUM Investor Conference

Biophytis Investor Conference Healthcare Sector Paris BIOMED Forum

Accesswire

Published on 05/07/2026 at 05:40, 3 hours 29 minutes ago

New Horizon Aircraft Ltd. Announces Pricing of $20 Million Offering of Common Shares
Published on 05/07/2026 at 02:00, 7 hours 9 minutes ago

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 9 hours 39 minutes ago

Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 10 hours 4 minutes ago

Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Published on 05/06/2026 at 23:00, 10 hours 9 minutes ago

Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 08:48, 20 minutes ago

Finnvera’s Annual General Meeting: New members to Finnvera’s Board of Directors and Supervisory Board
Published on 05/07/2026 at 08:36, 32 minutes ago

Cherry SE publishes results for the first quarter of 2026 – Operating profitability significantly improved
Published on 05/07/2026 at 08:30, 38 minutes ago

15 Years Delivering to You
Published on 05/07/2026 at 08:30, 38 minutes ago

Restoration: Grand Vision Media Holdings PLC
Published on 05/07/2026 at 08:30, 38 minutes ago

FRIWO with expected slow start to the year – recovery in the second half of 2026 thanks to planned new product launches

Les Echos

Published on 05/07/2026 at 07:43, 1 hour 25 minutes ago

ENGIE - Q1 2026 financial information
Published on 05/06/2026 at 18:00, 15 hours 8 minutes ago

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 15 hours 9 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
Published on 05/06/2026 at 17:45, 15 hours 24 minutes ago

Information concerning the total number of voting rights and shares 2026 04 30
Published on 05/06/2026 at 17:45, 15 hours 24 minutes ago

Declaration of voting rights at the end of April 2026

View all LES ECHOS COMFI WIRE